These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 26582149)
21. RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass. Kilgore KS; Shwartz CF; Gallagher MA; Steffen RP; Mosca RS; Bolling SF Circulation; 1999 Nov; 100(19 Suppl):II351-6. PubMed ID: 10567328 [TBL] [Abstract][Full Text] [Related]
22. Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. Velázquez CA; Chen QH; Citro ML; Keefer LK; Knaus EE J Med Chem; 2008 Mar; 51(6):1954-61. PubMed ID: 18314945 [TBL] [Abstract][Full Text] [Related]
23. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs. Pagel PS; Hettrick DA; Montgomery MW; Kersten JR; Steffen RP; Warltier DC J Pharmacol Exp Ther; 1998 Apr; 285(1):1-8. PubMed ID: 9535987 [TBL] [Abstract][Full Text] [Related]
24. The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats. Miyake M; Grinberg OY; Hou H; Steffen RP; Elkadi H; Swartz HM Adv Exp Med Biol; 2003; 530():319-29. PubMed ID: 14562728 [TBL] [Abstract][Full Text] [Related]
25. Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia. Eichelbrönner O; D'Almeida M; Sielenkämper A; Sibbald WJ; Chin-Yee IH Am J Physiol Heart Circ Physiol; 2002 Jul; 283(1):H92-101. PubMed ID: 12063279 [TBL] [Abstract][Full Text] [Related]
26. Effects of enhanced oxygen release from hemoglobin by RSR13 in an acute renal failure model. Burke TJ; Malhotra D; Shapiro JI Kidney Int; 2001 Oct; 60(4):1407-14. PubMed ID: 11576354 [TBL] [Abstract][Full Text] [Related]
27. Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies. Abdellatif KR; Chowdhury MA; Velázquez CA; Huang Z; Dong Y; Das D; Yu G; Suresh MR; Knaus EE Bioorg Med Chem Lett; 2010 Aug; 20(15):4544-9. PubMed ID: 20576432 [TBL] [Abstract][Full Text] [Related]
28. V-PROLI/NO, a prodrug of the nitric oxide donor, PROLI/NO. Chakrapani H; Showalter BM; Kong L; Keefer LK; Saavedra JE Org Lett; 2007 Aug; 9(17):3409-12. PubMed ID: 17658755 [TBL] [Abstract][Full Text] [Related]
29. Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity. Weiss RG; Mejia MA; Kass DA; DiPaula AF; Becker LC; Gerstenblith G; Chacko VP J Clin Invest; 1999 Mar; 103(5):739-46. PubMed ID: 10074492 [TBL] [Abstract][Full Text] [Related]
30. High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Safo MK; Moure CM; Burnett JC; Joshi GS; Abraham DJ Protein Sci; 2001 May; 10(5):951-7. PubMed ID: 11316875 [TBL] [Abstract][Full Text] [Related]
31. Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation. Khandelwal SR; Randad RS; Lin PS; Meng H; Pittman RN; Kontos HA; Choi SC; Abraham DJ; Schmidt-Ullrich R Am J Physiol; 1993 Oct; 265(4 Pt 2):H1450-3. PubMed ID: 8238433 [TBL] [Abstract][Full Text] [Related]
33. Effects of FI(O(2)) on hemodynamic responses and O(2) transport during RSR13-induced reduction in P(50). Eichelbrönner O; Sielenkämper A; D'Almeida M; Ellis CG; Sibbald WJ; Chin-Yee IH Am J Physiol; 1999 Jul; 277(1):H290-8. PubMed ID: 10409208 [TBL] [Abstract][Full Text] [Related]
34. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study. Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487 [TBL] [Abstract][Full Text] [Related]
35. X-ray crystallographic analyses of symmetrical allosteric effectors of hemoglobin: compounds designed to link primary and secondary binding sites. Safo MK; Boyiri T; Burnett JC; Danso-Danquah R; Moure CM; Joshi GS; Abraham DJ Acta Crystallogr D Biol Crystallogr; 2002 Apr; 58(Pt 4):634-44. PubMed ID: 11914488 [TBL] [Abstract][Full Text] [Related]
36. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Kavanagh BD; Khandelwal SR; Schmidt-Ullrich RK; Roberts JD; Shaw EG; Pearlman AD; Venitz J; Dusenbery KE; Abraham DJ; Gerber MJ Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1133-9. PubMed ID: 11240256 [TBL] [Abstract][Full Text] [Related]
37. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice. Rockwell S; Kelley M Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166 [TBL] [Abstract][Full Text] [Related]
38. Hantzsch 1,4-dihydropyridines containing a diazen-1-ium-1,2-diolate nitric oxide donor moiety to study calcium channel antagonist structure-activity relationships and nitric oxide release. Nguyen JT; Velázquez CA; Knaus EE Bioorg Med Chem; 2005 Mar; 13(5):1725-38. PubMed ID: 15698790 [TBL] [Abstract][Full Text] [Related]
39. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study. Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029 [TBL] [Abstract][Full Text] [Related]